|Composition||Glimepiride(1mg) + Metformin(500mg)|
|Medicine type||Antidiabetic(Type 2 diabetes)|
|Route of administration||Oral|
General uses of Glycomet-GP 1 Tablet PR
Glycomet-GP 1 Tablet PR is a combination of Two medicine. It is mainly used in the treatment of Type 2 Diabetes in adults.
This medicine helps to lower the blood glucose levels in diabetic patients.
Ingredients of Glycomet-GP 1 Tablet PR
Glimepiride: Glycomet-GP 1 Tablet PR contains Glimepiride(1mg). Glimepiride is a Sulfonylureas group of Anti-diabetic drugs. It helps in lowering the blood glucose levels in the body.
Metformin: Glycomet-GP 1 Tablet PR contain Metformin(500mg). Metformin is a Biguanides group of Anti-diabetic drugs. It is generally prescribed with other anti-diabetic drugs to treat Type 2 diabetes.
How does Glycomet-GP 1 Tablet PR work?/Mechanism of action
Glycomet-GP 1 Tablet PR is a combination of two medicines. The Glimepiride in this medicine is a Sulfonylureas group of drugs. It works by binding to SUR1(sulfonylureas receptors) in beta cells and inhibits the k+ sensitive channels. This leads to the opening of Ca2+ channels and therefore enhances the Ca2+ influx. This leads to an increase in insulin secretion. Increase insulin secretion helps in lowering the blood glucose levels in the body.
While Metformin In this medicine is a Biguanide class of anti-diabetic drug. It does not cause any effect on insulin secretion like other diabetic drugs. Metformin works in different ways to lower the Blood sugar levels in the body. It works by:
- Suppressing the hepatic gluconeogenesis and glucose output from the liver.
- Decreasing Intestinal absorption of Glucose.
- Improving Peripheral glucose utilization.
Side effects of Glycomet-GP 1 Tablet PR
The Glycomet-GP 1 Tablet PR may cause some side effects like:
- Stomach pain
- Hypoglycemia (low blood glucose level)
- Metallic taste(taste change)
When to Avoid Glycomet-GP 1 Tablet PR/Precautions
- Pregnant women must avoid the use of the Glycomet-GP 1 Tablet PR.
- It is not safe to consume this tablet with the use of alcohol.
- It is not advised to use Glycomet-GP 1 Tablet PR for patients with severe kidney disease.
- One who is hypersensitive to Glimepiride or Metformin should avoid the use of this tablet.
- As this medicine is only used to treat Type 2 diabetes, It is not advised to use this medicine in Type 1 diabetes mellitus.
How to use Glycomet-GP 1 Tablet PR
Take the dose of Glycomet-GP 1 Tablet PR as advised by your doctor.
This medicine should be taken with the food or just before or after having a meal.
Do not chew, crush, or break the tablet. Swallow it as a whole.
The best time to take this medicine Is with the food. You should take this medicine at the same time every day to get the most benefit.
Generally, the Glycomet-GP 1 Tablet PR does not have any major side effects. But In some patients, it may show one major side effect known as lactic acidosis. The metformin in this medicine is responsible for lactic acidosis. But this is rarely seen in the patients.
No, You should not stop the use of this medicine, when your blood glucose levels are controlled. You should consult your doctor about this and only your doctor will tell you, whether to stop using this medicine or not.
No, It is not safe to use this tablet during pregnancy
The Glycomet-GP 1 Tablet PR is an anti-diabetic medicine and is generally used in treating the Hyperglycemia(high blood glucose level). This medicine helps to lower the blood glucose(sugar) levels in the Body.
The Glycomet-GP 1 Tablet PR is a combination of two medicine i.e. Glimepiride and Metformin. It is generally used in the treatment of Hyperglycemia(a condition when the blood glucose levels in the body increase).
It helps to lower the blood glucose levels in the body. It is only advised to use in the treatment of type 2 diabetes.
Note: The above details about the Glycomet-GP 1 Tablet PR is for informative and study purposes. Do not use this medicine without consulting to doctor or pharmacist.
[…] The above article was about the Glycomet-GP 1 tablet in Hindi. To read in English, Click here. […]
Comments are closed.